Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 13/20 | 0.59 |
| ▸ | FGFR1 | P11362 | 12/20 | 0.59 |
| ▸ | PDGFRB | P09619 | 11/20 | 0.59 |
| ▸ | TLK2 | Q86UE8 | 1/20 | 0.59 |
| ▸ | SRC | P12931 | 15/20 | 0.55 |
| ▸ | LCK | P06239 | 9/20 | 0.55 |
| ▸ | YES1 | P07947 | 9/20 | 0.55 |
| ▸ | FYN | P06241 | 8/20 | 0.55 |
| ▸ | EGFR | P00533 | 2/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | MET | P08581 | 2/20 | 0.48 |
| ▸ | FLT3 | P36888 | 2/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.48 |
| ▸ | PLK4 | O00444 | 1/20 | 0.48 |
| ▸ | RIOK3 | O14730 | 1/20 | 0.48 |
| ▸ | CASK | O14936 | 1/20 | 0.48 |
| ▸ | GAK | O14976 | 1/20 | 0.48 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.48 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.48 |
| ▸ | MAP3K13 | O43283 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5410964 | 0.93 | KDR (0.60) | KDRFGFR1PDGFRBTLK2SRC | |
| SCHEMBL5407073 | 0.92 | KDR (0.62) | KDRFGFR1PDGFRBTLK2SRC | |
| SCHEMBL5396485 | 0.90 | KDR (0.58) | KDRFGFR1PDGFRBTLK2SRC | |
| SCHEMBL143097 | 0.86 | KDR (0.66) | KDRFGFR1PDGFRBTLK2SRC | |
| SCHEMBL5396486 | 0.85 | KDR (0.61) | KDRFGFR1PDGFRBTLK2SRC | |
| SCHEMBL5417729 | 0.85 | MET (0.66) | KDRFGFR1PDGFRBTLK2SRC | |
| SCHEMBL5417668 | 0.85 | SRC (0.59) | KDRFGFR1PDGFRBTLK2SRC | |
| SCHEMBL5405519 | 0.84 | MET (0.61) | KDRFGFR1PDGFRBTLK2SRC | |
| SCHEMBL5412097 | 0.84 | MET (0.70) | KDRFGFR1PDGFRBTLK2SRC | |
| SCHEMBL142917 | 0.81 | FGFR1 (0.59) | KDRFGFR1PDGFRBTLK2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7157577-B2 | 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors | SUGEN INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157577-B2 | 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors | SUGEN INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157577-B2 | 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors | SUGEN INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20040266843-A1 | Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK) | SUGEN, INC. | 2004-12-30 | — | — | US | disclosed |
| US-20040204407-A1 | 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors | SUGEN INC. | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204407-A1 | 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors | DMPK, MAP3K20, PHKG1 | KDR 1657/4885FGFR1 1118/4885PDGFRB 913/4885 |
| US-20040266843-A1 | Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK) | CHEK2, CHEK1, ATM | KDR 1541/4885FGFR1 1253/4885PDGFRB 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.